Kazia Therapeutics Book/Share
What is the Book/Share of Kazia Therapeutics?
The Book/Share of Kazia Therapeutics Limited is 0.07
What is the definition of Book/Share?
Book value per share is a company’s assets minus liabilities divided by the number of shares outstanding.
mrq (most recent quarter)
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Book/Share of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with book/share similar to Kazia Therapeutics
- Signal Gold has Book/Share of 0.07
- Absolute Software has Book/Share of 0.07
- Luxxu has Book/Share of 0.07
- Manfield Chemical has Book/Share of 0.07
- V1 has Book/Share of 0.07
- SRG Graphite has Book/Share of 0.07
- Kazia Therapeutics has Book/Share of 0.07
- Saferoads has Book/Share of 0.07
- K9 Gold has Book/Share of 0.07
- TWC Tech II has Book/Share of 0.07
- Mineworx Technologies has Book/Share of 0.07
- China Greenland Broad Greenstate has Book/Share of 0.07
- Patriot One Technologies has Book/Share of 0.07